Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide in High-Risk Smoldering Multiple Myeloma
NCT03952832Phase 2Withdrawn
- Sponsor
- City of Hope
- Start
- Dec 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of leflunomide in smoldering multiple myeloma (SMM), sponsored by City of Hope. Primary endpoints: Progression to multiple myeloma at 2 years and Overall Survival at 2 years. Planned start Dec 2019; status: withdrawn.
02
Drugs
leflunomide
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT03952832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03952832.